Project

Nutrabolt Research & Development

Updates
0 new
0
Recommendations
0 new
0
Followers
0 new
1
Reads
0 new
29

Project log

Richard Kreider
added 2 research items
In a double-blind, randomized and crossover manner, 25 resistance-trained participants ingested a placebo (PLA) beverage containing 12 g of dextrose and a beverage (RTD) containing caffeine (200 mg), β-alanine (2.1 g), arginine nitrate (1.3 g), niacin (65 mg), folic acid (325 mcg), and Vitamin B12 (45 mcg) for 7-days, separated by a 7–10-day. On day 1 and 6, participants donated a fasting blood sample and completed a side-effects questionnaire (SEQ), hemodynamic challenge test, 1-RM and muscular endurance tests (3 × 10 repetitions at 70% of 1-RM with the last set to failure on the bench press (BP) and leg press (LP)) followed by ingesting the assigned beverage. After 15 min, participants repeated the hemodynamic test, 1-RM tests, and performed a repetition to fatigue (RtF) test at 70% of 1-RM, followed by completing the SEQ. On day 2 and 7, participants donated a fasting blood sample, completed the SEQ, ingested the assigned beverage, rested 30 min, and performed a 4 km cycling time-trial (TT). Data were analyzed by univariate, multivariate, and repeated measures general linear models (GLM), adjusted for gender and relative caffeine intake. Data are presented as mean change (95% CI). An overall multivariate time × treatment interaction was observed on strength performance variables (p = 0.01). Acute RTD ingestion better maintained LP 1-RM (PLA: −0.285 (−0.49, −0.08); RTD: 0.23 (−0.50, 0.18) kg/kgFFM, p = 0.30); increased LP RtF (PLA: −2.60 (−6.8, 1.6); RTD: 4.00 (−0.2, 8.2) repetitions, p = 0.031); increased BP lifting volume (PLA: 0.001 (−0.13, 0.16); RTD: 0.03 (0.02, 0.04) kg/kgFFM, p = 0.007); and, increased total lifting volume (PLA: −13.12 (−36.9, 10.5); RTD: 21.06 (−2.7, 44.8) kg/kgFFM, p = 0.046). Short-term RTD ingestion maintained baseline LP 1-RM (PLA: −0.412 (−0.08, −0.07); RTD: 0.16 (−0.50, 0.18) kg/kgFFM, p = 0.30); LP RtF (PLA: 0.12 (−3.0, 3.2); RTD: 3.6 (0.5, 6.7) repetitions, p = 0.116); and, LP lifting volume (PLA: 3.64 (−8.8, 16.1); RTD: 16.25 (3.8, 28.7) kg/kgFFM, p = 0.157) to a greater degree than PLA. No significant differences were observed between treatments in cycling TT performance, hemodynamic assessment, fasting blood panels, or self-reported side effects.
Background: We examined the effects of ingesting two preworkout supplements (PWSs) on selective attention and response inhibition, perceived exercise readiness (herein, readiness), and exercise performance-related parameters. Methods: Resistance-trained participants (N = 19) were randomized to a double-blind, crossover (7-day washout) placebo (PLA)-controlled study supplementing with (1) PLA; (2) PWS [beta-alanine (3.2 g), arginine alpha ketoglutarate (2.0 g), creatine nitrate (2.0 g), ascorbic acid (500 mg), N-acetyl tyrosine (300 mg), caffeine (300 mg), tetramethyluric acid (10 mg), Mucuna pruriens extract standardized for 15% l-Dopa (1.0 g), theacrine (10 mg), pyridoxal 5-phosphate (1.48 mg), folic acid (0.50 mg), and methylcobalamin (1.8 mg)]; and (3) PWS150 at ∼150% the PWS dose. Primary outcomes were Stroop test responses for congruent, incongruent, and interference tasks. Secondary outcomes were readiness and exercise performance (bench and leg press/Wingate). Data were analyzed by general linear models and presented as mean (standard deviation) or mean change [95% confidence interval, CI]. Results: Significant improvements in Stroop word testing were observed for PWS (6.57, 95% CI [1.36–11.8]) and PWS150 (11.5, 95% CI [6.26–16.6]), but not PLA (1.31, 95% CI [−3.89 to 6.52]). Significant changes in Stroop color testing were observed for PWS150 (8.1, 95% CI [4.52–11.6]) and PLA (4.47, 95% CI [0.89–8.05]), but not PWS (2.31, 95% CI [−1.26 to 5.89]). Similar results were observed for word–color. When all domains were summed, PWS150 (27.42 counts, 95% CI [16.08–38.76]) and PWS (12.26 counts, 95% CI [0.92–23.60]) showed significant improvements, but not PLA (11.26 counts, 95% CI [−0.077 to 22.60]). No significant changes in readiness, exercise performance, or adverse changes were otherwise observed. Conclusion: Consistent improvements in selective attention and response inhibition were observed with PWS150, but not readiness or exercise performance.